New drug shows promise for rare inflammatory disease
NCT ID NCT04602598
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested the drug zanubrutinib in 10 people with IgG4-related disease, a condition that causes swelling in glands and other organs. The goal was to see if the drug could reduce gland size and inflammation over 24 weeks. Researchers measured changes using PET-MRI scans.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- zanubrutinib
- What this could lead to
- If successful, this could point toward a new treatment option for IgG4-related disease, reducing gland swelling and inflammation.
- What could go wrong
- This is a small, early-phase trial with only 10 participants, so results may not apply to everyone. The drug may not work as hoped or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGG4-RELATED DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Stanford University
Palo Alto, California, 94304, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug aims to stop IgG4 disease relapses without Long-Term steroids
- Experimental CAR-T injection aims to tame autoimmune diseases
- Scientists investigate immune cell role in rare IgG4 disease
- Old drug, new hope: could filgotinib tame rare immune diseases?
- New scan could shine a light on hidden inflammation
- New hope for IgG4 patients: which drug combo works best?